Company intelligence
eGenesis
Restoring life after organ failure.
About eGenesis
eGenesis is revolutionizing the field of transplantation with an unparalleled, multiplexed gene editing platform for the development of human-compatible organs, tissues and cells. Harnessing the latest gene-editing techniques, eGenesis’ mission is to solve the global organ shortage crisis by developing a scalable alternative to allotransplantation. eGenesis is reinvigorating the field of xenotransplantation by addressing the key virology and immunology hurdles that have prevented its advancement to date, and is developing commercially-viable products to save and improve the lives of patients who are waiting for an organ transplant.
Verified activity
Signals from eGenesis
4 published signals
Presence & Recognition
eGenesis president and CEO Michael Curtis spoke with Forbes about recent kidney program updates.
Reported by eGenesis
Research & Knowledge
eGenesis published the experience of patient Tim Andrews in The Lancet, providing clinical evidence that genetically engineered porcine kidneys can preserve the opportunity for a subsequent human kidney transplant.
Reported by eGenesis
Research & Knowledge
eGenesis announced clinical updates from its ongoing Expanded Access study of EGEN-2784, a genetically engineered porcine kidney for patients with kidney failure.
Reported by eGenesis
Presence & Recognition
eGenesis was featured in The New York Times highlighting an important milestone for organ transplantation involving Tim Andrews, a genetically engineered porcine kidney.
Reported by eGenesis